Transactions of Managers and Closely Associated Persons

Alvotech closed a public offering raising $165 million in aggregate proceeds, with underwriters fully exercising their option to purchase additional shares. The offering included a concurrent private placement where Celtic Lux Holdings acquired 10,133,333 shares at $3.75 per share.

06/22/2026, 6:48 PM • GlobeNewswire

Viðskipti stjórnenda og tengdra aðila

Alvotech successfully closed a public offering raising $165 million in aggregate, with underwriters fully exercising their option to purchase additional shares. The offering included a concurrent private placement where Celtic Lux Holdings purchased 10.133 million shares at $3.75 per share on June 16, 2026.

06/22/2026, 6:48 PM • GlobeNewswire

Alvotech tilkynnir um verð og úthlutun hlutabréfa að andvirði um 152 milljónir dollara í útboði í Bandaríkjunum og lokuðu útboði til fagfjárfesta á Evrópska efnahagssvæðinu

Alvotech (NASDAQ: ALVO) announced a $152 million share offering, comprising an $85 million public offering in the US at $3.75 per share and a $67 million private placement to institutional investors in the EEA. The company plans to use proceeds for biosimilar drug development, working capital, and operational expenses. BofA Securities, Jefferies, and Evercore ISI are joint underwriters.

06/15/2026, 11:50 PM • GlobeNewswire

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

Alvotech priced a $152 million public offering of 22.67 million ordinary shares at $3.75 per share, with an additional concurrent private placement of 17.83 million shares at the same price expected to raise approximately $67 million. The company plans to use net proceeds for biosimilar development, working capital, and potential debt repayment. The offering is expected to close on June 17, 2026, with the private placement closing around June 25, 2026.

06/15/2026, 11:50 PM • GlobeNewswire

Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?

Teva Pharmaceutical has rebounded 97% in 12 months driven by its expanding biosimilars lineup and branded drugs like Austedo. However, the stock now trades at a fair 25x P/E ratio with 2026 revenue expected to be flat to lower. While biosimilars could grow to $800 million by 2027, the narrow-margin business faces intense competition and the easy gains may already be priced in. The analyst recommends watching but not buying.

06/12/2026, 4:05 PM • The Motley Fool

Alvotech files Annual Report with the SEC

Alvotech (NASDAQ: ALVO), an Iceland-based biotechnology company specializing in biosimilar medicines, has filed its Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission. The company has five approved and marketed biosimilars and nine additional candidates in development across multiple therapeutic areas.

03/30/2026, 7:58 PM • GlobeNewswire

Alvotech birtir ársreikning á eyðublaði 20-F

Alvotech announced the publication of its 2025 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The report is available on the SEC website and Alvotech's investor relations page.

03/30/2026, 7:58 PM • GlobeNewswire

Alvotech Files Annual Report with the SEC

Alvotech (NASDAQ: ALVO), an Iceland-based biotechnology company specializing in biosimilar medicines, has filed its Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission. The company has five approved and marketed biosimilars and nine additional candidates in development, supported by a global network of strategic commercial partnerships.

03/30/2026, 7:55 PM • GlobeNewswire

Alvotech birtir ársskýrslu fyrir árið 2025

Alvotech (NASDAQ: ALVO), an Icelandic biotech company founded by Róbert Wessman, has filed its Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission. The company focuses on developing and manufacturing biosimilar medications for patients worldwide, with operations spanning major markets including the United States, Europe, Asia, Latin America, Africa, and the Middle East.

03/30/2026, 7:55 PM • GlobeNewswire

Alvotech Publishes 2025 Annual Report

Alvotech (NASDAQ: ALVO), an Iceland-based biotechnology company specializing in biosimilar medicines, has published and filed its 2025 Annual Report with the SEC on Form 20-F. The company currently has five approved and marketed biosimilars and nine additional candidates in development across multiple therapeutic areas.

03/30/2026, 7:55 PM • GlobeNewswire

ALVO INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alvotech

Law firm Kirby McInerney LLP is investigating Alvotech following the company's receipt of a complete response letter from the FDA on November 3, 2025, related to a failed facility inspection in July 2025. The news triggered a significant stock decline of 34.25%, dropping from $7.65 to $5.03 per share. The firm is determining whether securities law violations occurred and is seeking investors to participate in potential litigation.

02/23/2026, 8:00 PM • GlobeNewswire

Alvotech Announces Increase in Number of Own Shares

Alvotech announced a share capital increase of USD 125,000 through the issuance of 12.5 million ordinary shares purchased by its subsidiary at USD 5.2 per share. The shares will be held as treasury shares to support the company's financial obligations including convertible bonds, warrants, and employee compensation. Total issued shares increased from 334 million to 346.5 million, while outstanding shares remained unchanged at 330.3 million.

02/11/2026, 11:00 AM • GlobeNewswire

Alvotech tilkynnir um aukningu í fjölda eigin bréfa

Alvotech announced the issuance of 12.5 million new shares to its subsidiary at $5.2 per share, increasing treasury stock to support financial obligations including warrants and employee incentives. The company also reported positive top-line results from a pivotal pharmacokinetic study for AVT80, a proposed biosimilar to Entyvio®, meeting all primary endpoints.

02/11/2026, 11:00 AM • GlobeNewswire

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following the company's November 2, 2025 announcement that the FDA issued a complete response letter for its AVT05 biologics license application, citing manufacturing deficiencies. The stock fell 34% on November 3, 2025, and investors are being encouraged to join a prospective class action lawsuit.

02/05/2026, 5:40 PM • GlobeNewswire

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following allegations of materially misleading business information. The investigation was triggered after Alvotech received a complete response letter from the FDA on November 2, 2025, regarding deficiencies in its Biologics License Application for AVT05, causing the stock to fall 34% on November 3, 2025. The firm is preparing a class action lawsuit to recover investor losses.

02/02/2026, 6:55 PM • GlobeNewswire